Pier 88 Investment Partners LLC Has $1.58 Million Stock Position in Certara, Inc. $CERT

Pier 88 Investment Partners LLC raised its position in shares of Certara, Inc. (NASDAQ:CERT) by 83.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 128,960 shares of the company’s stock after buying an additional 58,820 shares during the quarter. Pier 88 Investment Partners LLC owned 0.08% of Certara worth $1,576,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Wasatch Advisors LP lifted its position in shares of Certara by 45.7% in the 2nd quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock valued at $158,335,000 after acquiring an additional 4,244,230 shares in the last quarter. Marshall Wace LLP raised its stake in Certara by 1,430.6% during the 2nd quarter. Marshall Wace LLP now owns 1,512,343 shares of the company’s stock valued at $17,694,000 after purchasing an additional 1,413,538 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of Certara by 27.1% in the second quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after purchasing an additional 1,165,064 shares in the last quarter. Teacher Retirement System of Texas raised its position in Certara by 25.3% during the second quarter. Teacher Retirement System of Texas now owns 5,674,485 shares of the company’s stock valued at $66,391,000 after buying an additional 1,145,554 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH purchased a new stake in Certara in the 3rd quarter worth about $11,899,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Stock Performance

CERT stock opened at $10.11 on Tuesday. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of 144.43 and a beta of 1.46. Certara, Inc. has a 12 month low of $8.02 and a 12 month high of $15.69. The firm has a 50 day moving average of $9.12 and a two-hundred day moving average of $10.42.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $104.62 million for the quarter, compared to the consensus estimate of $104.53 million. Certara had a net margin of 2.62% and a return on equity of 5.18%. During the same quarter last year, the firm earned $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. As a group, equities analysts anticipate that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Redburn Partners set a $10.00 target price on Certara in a report on Friday, November 21st. Leerink Partners upgraded shares of Certara from a “market perform” rating to an “outperform” rating and set a $13.00 price objective on the stock in a research note on Tuesday, January 6th. Wall Street Zen lowered shares of Certara from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. Morgan Stanley lowered their price target on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, December 18th. Finally, Stephens lowered their price target on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $12.58.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.